2. Patients (males and females, ages 0 - 99) with known (based on hormonal, clinical and/or genetic testing) CAH due to 21-hydroxylase deficiency, 11-hydroxylase deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency. Patients with both classic and nonclassic patients are eligible.